Form 4: ImmunityBio CAO's RSU Vesting and Share Sale
Insider Transaction Report
ImmunityBio's Chief Accounting Officer, Regan J. Lauer, reported the vesting of restricted stock units and a subsequent sale of shares for tax purposes.
Summary
- Regan J. Lauer, Chief Accounting Officer of ImmunityBio, Inc. (IBRX), reported transactions related to her beneficial ownership.
- On February 10, 2026, 5,482 restricted stock units (RSUs) vested, converting into an equal number of common shares.
- Concurrently, 2,257 shares of common stock were disposed of at a price of $6.93 per share to cover tax withholding obligations related to the RSU vesting.
- Following these transactions, Regan J. Lauer directly holds 113,483 shares of common stock.
- Additionally, Regan J. Lauer beneficially owns 10,965 derivative securities, representing unvested restricted stock units.
- The vesting commencement date for this RSU award was February 10, 2025, with vesting scheduled in annual installments over three years.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing a routine compensation transaction for a company officer that does not provide new material information regarding the company's operational or financial performance.
Positives
- The vesting of 5,482 restricted stock units represents a scheduled compensation event for the Chief Accounting Officer, aligning management's interests with shareholder value.
Negatives
- The disposition of 2,257 shares was for tax withholding purposes, a routine event following RSU vesting and not indicative of a negative outlook on the company.
Industry Context
StockSavvy.ai notes that this Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. Such transactions are common compensation practices in the biotechnology industry and generally do not signal changes in company fundamentals or strategic direction.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Regan J. Lauer granted a Power of Attorney to several individuals (Richard Adcock, David C. Sachs, Philip LoScalzo, Benjamin J. Capps, and Brandon Shaw) to prepare, execute, and submit SEC filings on her behalf. | October 8, 2025 | This administrative change streamlines compliance with SEC reporting requirements for the Chief Accounting Officer, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders: Minimal direct impact, as this is a routine compensation event for an executive and does not reflect a change in company strategy or financial health.
- Employees: Reinforces the company's compensation structure for executives, potentially impacting morale and retention.
Next Steps
- Remaining restricted stock units are scheduled to vest in equal annual installments on the first and second anniversaries of the vesting commencement date (February 10, 2025), with the final portion vesting on the third anniversary.
Key Dates
| Date | Description |
|---|---|
| October 8, 2025 | Date Regan J. Lauer executed a Power of Attorney for SEC filings. |
| February 10, 2025 | Vesting commencement date for the reported Restricted Stock Unit award. |
| February 10, 2026 | Date of RSU vesting and subsequent share disposition for tax withholding. |
| February 12, 2026 | Date the Form 4 was signed and filed. |
Recommendation
holdThis Form 4 reports a routine vesting of restricted stock units and a subsequent sale of shares for tax withholding by a company officer. It does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation.
Keywords
ImmunityBio, IBRX, Form 4, Restricted Stock Units, RSU, Insider Transaction, Stock Vesting, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.